However, other clinical trials have revealed that the Nrf2 activator BM shows cardiotoxicity when treating diabetes mellitus [58], and resveratrol shows no effect on chronic kidney disease [59]. This evidence concerns the gene NFE2L2 and diabetes mellitus.